

# Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/RA7907DB3765EN.html>

Date: December 2022

Pages: 45

Price: US\$ 2,000.00 (Single User License)

ID: RA7907DB3765EN

## Abstracts

Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Drugs In Development, 2022, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 2 molecules, respectively.

Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).

The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Recurrent Malignant

Glioma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Recurrent Malignant Glioma - Overview
- Recurrent Malignant Glioma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Recurrent Malignant Glioma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
- Candel Therapeutics Inc
- Hebei Senlang Biotechnology Co Ltd
- Immunomic Therapeutics Inc
- Moleculin Biotech Inc
- Oblato Inc
- PharmAbcine Inc
- Smerud Medical Research International AS
- Stella Pharmaceuticals Pvt Ltd
- Sumitomo Pharma Co Ltd
- Recurrent Malignant Glioma - Drug Profiles
- 2141 V-11 - Drug Profile
- Product Description
- Mechanism Of Action
- 2X-111 - Drug Profile
- Product Description
- Mechanism Of Action
- bevacizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- borofalan - Drug Profile
- Product Description
- Mechanism Of Action

CAN-3110 - Drug Profile

Product Description

Mechanism Of Action

disufenton sodium - Drug Profile

Product Description

Mechanism Of Action

DSP-0390 - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target EphA2 for Recurrent Malignant Glioma - Drug Profile

Product Description

Mechanism Of Action

ITI-1000 - Drug Profile

Product Description

Mechanism Of Action

Memory Enriched T Cells - Drug Profile

Product Description

Mechanism Of Action

SENL-006 - Drug Profile

Product Description

Mechanism Of Action

Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile

Product Description

Mechanism Of Action

WP-1066 - Drug Profile

Product Description

Mechanism Of Action

Recurrent Malignant Glioma - Dormant Projects

Recurrent Malignant Glioma - Discontinued Products

Recurrent Malignant Glioma - Product Development Milestones

Featured News & Press Releases

Apr 22, 2022: Moleculin obtains FDA clearance for Phase I glioma treatment trial

Dec 06, 2017: Moleculin's WP1066 Drug receives \$2 million Private Grant

Dec 05, 2017: Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance

Apr 21, 2017: Japan's Ministry of Health, Labour and Welfare Announces SAKIGAKE Designation For Stella Pharma's Cancer Drug

Appendix

Methodology

Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Recurrent Malignant Glioma, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Recurrent Malignant Glioma - Pipeline by Candel Therapeutics Inc, 2022  
Recurrent Malignant Glioma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022  
Recurrent Malignant Glioma - Pipeline by Immunomic Therapeutics Inc, 2022  
Recurrent Malignant Glioma - Pipeline by Moleculin Biotech Inc, 2022  
Recurrent Malignant Glioma - Pipeline by Oblato Inc, 2022  
Recurrent Malignant Glioma - Pipeline by PharmAbcine Inc, 2022  
Recurrent Malignant Glioma - Pipeline by Smerud Medical Research International AS, 2022  
Recurrent Malignant Glioma - Pipeline by Stella Pharmaceuticals Pvt Ltd, 2022  
Recurrent Malignant Glioma - Pipeline by Sumitomo Pharma Co Ltd, 2022  
Recurrent Malignant Glioma - Dormant Projects, 2022  
Recurrent Malignant Glioma - Dormant Projects, 2022 (Contd..1)  
Recurrent Malignant Glioma - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Recurrent Malignant Glioma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Recurrent Malignant Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/RA7907DB3765EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RA7907DB3765EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

